What are the latest clinical trials for Cervical Cancer in 2026

Latest Clinical Trials for Cervical Cancer in 2026

I appreciate your question about current clinical trials. Based on the most recent NCCN Guidelines (Version 1.2026, updated October 2025), I can share what's known about emerging treatment approaches and ongoing research, though I should note that specific trial enrollment information changes frequently.

Key Treatment Advances Being Studied

According to the NCCN Guidelines for Cervical Cancer, several important clinical trial areas are actively being pursued:

Immunotherapy Combinations

Recent trials have shown promising results with checkpoint inhibitors (drugs that help your immune system fight cancer):

• Pembrolizumab-based combinations: The KEYNOTE-826 study demonstrated that pembrolizumab combined with chemotherapy and/or bevacizumab (a drug that blocks blood vessel growth) is effective for persistent, recurrent, or metastatic cervical cancer, especially for tumors expressing PD-L1 (a specific protein marker).

• Nivolumab studies: The CheckMate-358 trial evaluated nivolumab in advanced cervical cancer patients who had received prior treatment, showing an objective response rate of 26.3%.

Targeted Therapy Approaches

The NCCN Guidelines highlight emerging research in:

• HER2-targeted therapies: For cervical cancers with HER2 mutations or overexpression
• NTRK fusion-positive cancers: Targeted treatments for rare cervical cancers with specific genetic changes
• Tissue Factor Pathway Inhibitor (TisotumabVedotin): Being studied in combination with other drugs for recurrent/metastatic disease

Biomarker-Driven Treatment

A major shift in cervical cancer care involves testing for specific biomarkers to guide treatment selection:

• PD-L1 testing is now recommended by NCCN for patients with recurrent, progressive, or metastatic disease
• Comprehensive molecular profiling using FDA-approved assays helps identify which patients may benefit from specific targeted therapies

How to Find Current Trials

For the most up-to-date information on active clinical trials enrolling patients in 2026, I recommend:

1. ClinicalTrials.gov - The official U.S. registry where you can search by cancer type, location, and treatment type
2. NCI Cancer Information Service (CIS) - Available through the National Cancer Institute
3. Your oncology team - They can identify trials you may be eligible for based on your specific diagnosis and medical history

Questions to Ask Your Care Team

Since clinical trial availability and eligibility vary by location and individual case:

1. "Are there any clinical trials available for my specific type and stage of cervical cancer?"
2. "What biomarker testing do you recommend for my cancer, and how might results guide treatment options?"
3. "Would I be a candidate for any immunotherapy or targeted therapy trials?"
4. "What are the potential benefits and risks of participating in a clinical trial versus standard treatment?"
5. "How would a trial affect my treatment schedule and follow-up care?"

Important Context

According to NCCN Guidelines, the field of cervical cancer treatment is evolving rapidly. The emergence of immunotherapy and targeted therapies has significantly improved outcomes, particularly for patients with recurrent or metastatic disease. However, your oncologist will determine which trials—if any—are appropriate for YOUR specific situation based on your cancer stage, type, biomarker status, prior treatments, and overall health.

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions about clinical trial participation.